Advances in Biomedical Analytics: Real-World Evidence, Digital Health, Robotics and Artificial Intelligence

Dear Colleague,

Following the 21st Century Cures Act in the United States (US), real-world evidence (RWE) has been well defined. According to the US Food and Drug Administration, real-world data (RWD) are “data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources”. RWE is “clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD”. RWD can be from a variety of sources, such as “data derived from electronic health records, medical claims data, data from product or disease registries, and data gathered from other sources (such as digital health technologies) that can inform on health status”.

With the great emphasis on RWD and RWE has come a variety of challenges and novel ways to optimize and enhance patient-centricity in the development of new therapeutics, whether by informing target selection, designing randomized controlled trials (RCTs), or enabling personalized medicine. This includes novel ways to evaluate disease burden and patient heterogeneity, increased ability to access, generate and leverage fit-for-purpose data sources, and opportunities to harness cloud computing for enhanced scalability and interactivity of digital tools.  This includes novel means of gathering data, such as decentralized RCT’s to facilitate broader patient access, electronic patient-reported outcomes (PROs) capture, digital wearables, and bring-your-own-device (BYOD) designs. With this increase in volume and variety of patient-centric data also come increasing opportunities to adopt and deploy artificial intelligence (AI), machine learning (ML), deep learning (DL), digital health, robotics, and medical devices to unlock novel and timely insights.

This Special Issue focuses on the latest advancements in RWE, digital innovation and AI to enable and improve health care.

Dr. Kelly H. Zou
Dr. Susan Halabi
Dr. Aaron Galaznik
Dr. Kiyoyuki Chinzei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• real-world data
• real-world evidence
• big data
• randomized controlled trials
• patient-reported outcomes
• digital innovation
• digital health
• robotics
• medical devices
• artificial intelligence
• machine learning
• deep learning